Company / PP&E (Net)
Theravance Biopharma, Inc. PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$5.9M
FY2025
5-year range
$5.9M / $13.7M
FY2021-FY2025
Trend
-20.5%
vs FY2024
Sector context
#107 of 193
Health Care
What the data says
At $6M, Theravance Biopharma, Inc.'s pp&e (net) ranks #107 of 193 in the Health Care sector. PP&E (Net) has declined for 5 consecutive years, from $16M in FY2020 to $6M in FY2025.
Based on SEC 10-K filings.
$6M in FY2025 with a 5-year CAGR of -18.5%.
Declined from $9M to $6M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -20.8%
- 5-Year CAGR
- -18.5%
- 10-Year CAGR
- -
Sector benchmark
#107 of 193 in Health CareTop 55% of 193This company $5.9M Sector average $777.6M
▼
-99.2% below sector average
Key checks
Key Insights
- Theravance Biopharma, Inc.'s pp&e (net) has declined for 5 consecutive years.
- 5-year CAGR of -18.5%, indicating a declining trend.
- In FY2025, pp&e (net) decreased 20.5% year-over-year.
- Ranks #107 out of 193 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $5.9M | -20.5% |
| FY2024 | $7.4M | -18.2% |
| FY2023 | $9.1M | -23.6% |
| FY2022 | $11.9M | -13.0% |
| FY2021 | $13.7M | -16.8% |
| FY2020 | $16.4M | +29.9% |
| FY2019 | $12.6M | -4.0% |
| FY2018 | $13.2M | +29.7% |
| FY2017 | $10.2M | +20.1% |
| FY2016 | $8.5M | -11.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026